Sponsor

MedSIR

Clinical research sponsor

Published trials52
Recruiting shown4
Roles2
SourceClinicalTrials.gov

Clinical trials

52 shown
Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerNCT07195227 · lead sponsor · 2026-03-24
RECRUITING
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeNCT06486883 · lead sponsor · 2025-06-30
RECRUITING
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisNCT06315010 · lead sponsor · 2025-06-27
RECRUITING
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.NCT06382948 · lead sponsor · 2024-12-05
RECRUITING
A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.NCT07619066 · lead sponsor · 2026-10-04
NOT_YET_RECRUITING
Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast CancerNCT07494448 · lead sponsor · 2026-07-01
NOT_YET_RECRUITING
Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast CancerNCT07367178 · lead sponsor · 2026-07-01
NOT_YET_RECRUITING
Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain MetastasesNCT07178938 · lead sponsor · 2026-04-30
NOT_YET_RECRUITING
Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBCNCT07134556 · lead sponsor · 2026-04-01
WITHDRAWN
Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain MetastasesNCT06676917 · lead sponsor · 2025-06-01
WITHDRAWN
Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast CancerNCT06604858 · lead sponsor · 2025-05-29
COMPLETED
Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast CancerNCT06612203 · lead sponsor · 2025-01-17
ACTIVE_NOT_RECRUITING
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerNCT06172127 · lead sponsor · 2024-07-22
ACTIVE_NOT_RECRUITING
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain MetastasesNCT06048718 · lead sponsor · 2024-06-05
ACTIVE_NOT_RECRUITING
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationNCT05708235 · lead sponsor · 2024-04-01
ACTIVE_NOT_RECRUITING
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal DiseaseNCT05865990 · lead sponsor · 2023-11-24
COMPLETED
Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%NCT05659563 · lead sponsor · 2023-07-20
COMPLETED
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With EribulinNCT05810870 · lead sponsor · 2023-05-24
ACTIVE_NOT_RECRUITING
Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMEDNCT05520723 · lead sponsor · 2023-02-06
COMPLETED
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)NCT06525675 · lead sponsor · 2022-07-18
COMPLETED
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast CancerNCT05227131 · lead sponsor · 2022-05-15
WITHDRAWN
POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast CancerNCT04826016 · lead sponsor · 2022-03-16
WITHDRAWN
Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 StatusNCT05217381 · lead sponsor · 2022-02-22
COMPLETED
Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerNCT04733118 · lead sponsor · 2021-08-05
ACTIVE_NOT_RECRUITING
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaLNCT04603183 · lead sponsor · 2021-06-02
COMPLETED
CB-103 Plus NSAI In Luminal Advanced Breast CancerNCT04714619 · lead sponsor · 2021-05-06
TERMINATED
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC PatientsNCT04300790 · lead sponsor · 2020-10-23
COMPLETED
Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast CancerNCT04464174 · lead sponsor · 2020-10-08
COMPLETED
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBCNCT04408118 · lead sponsor · 2020-10-05
COMPLETED
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)NCT04332744 · lead sponsor · 2020-09-02
COMPLETED
Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)NCT04240106 · lead sponsor · 2020-06-15
COMPLETED
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] DiseaseNCT04420598 · lead sponsor · 2020-05-25
COMPLETED
Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -NCT03819010 · lead sponsor · 2019-05-07
COMPLETED
Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast CancerNCT03931551 · lead sponsor · 2019-04-30
TERMINATED
Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer PatientsNCT03795012 · lead sponsor · 2019-04-30
TERMINATED
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)NCT03809988 · lead sponsor · 2019-04-05
COMPLETED
A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single AgentNCT03367689 · lead sponsor · 2018-04-17
TERMINATED
Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & TaxanesNCT03222856 · lead sponsor · 2017-12-14
COMPLETED
Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBCNCT03184090 · lead sponsor · 2017-06-28
COMPLETED
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.NCT03161353 · lead sponsor · 2017-06-26
ACTIVE_NOT_RECRUITING
Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer PatientsNCT03328884 · lead sponsor · 2017-05-02
COMPLETED
Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 StatusNCT03002220 · lead sponsor · 2016-12-21
COMPLETED
Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790MNCT02841579 · lead sponsor · 2016-09-02
COMPLETED
Spanish Lung Liquid vs. Invasive Biopsy Program (SLLIP)NCT03248089 · lead sponsor · 2016-07-01
COMPLETED
T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerNCT02562378 · lead sponsor · 2015-10-01
COMPLETED
Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast CancerNCT02491983 · lead sponsor · 2015-08-01
COMPLETED
Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line TreatmentNCT02061085 · lead sponsor · 2013-07-01
COMPLETED
Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or LapatinibNCT02056080 · lead sponsor · 2013-01-01
COMPLETED
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With ImmunotherapyNCT05715229 · collaborator · 2023-09-29
TERMINATED
Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.NCT04358237 · collaborator · 2020-09-21
COMPLETED
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCNCT05498896 · collaborator · 2018-12-19
ACTIVE_NOT_RECRUITING
Pre-operative Immunotherapy Combination Strategies in Breast CancerNCT03395899 · collaborator · 2017-12-21
COMPLETED

Sponsor roles

lead sponsor48
collaborator4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.